Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/7261e095d91ee459981b372c92d80d64e6449197"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more"></iframe>

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

More from Health

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug

STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds

Why this year’s flu season could be hitting teens and young adults hard

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

More from Health

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug

STAT+: Pharma is a &#8216;mixed bag&#8217; when providing drug access to low- and middle-income countries, analysis finds

Why this year’s flu season could be hitting teens and young adults hard

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds